Despite guideline recommendations, evidence suggests there is inadequate testing for primary aldosteronism among patients with treatment-resistant hypertension. In a recent study, researchers examined the...
The new treatment is the first FDA-approved drug to address the overproduction of cortisol in Cushing disease by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.
Researchers aimed to determine whether target treatment to prevent new-onset atrial fibrillation was effective among patients with primary aldosteronism compared with controls with essential hypertension. ...
By Marilynn Larkin
NEW YORK (Reuters Health) - Benign, so-called "nonfunctional" adrenal tumors may increase the risk of type 2 diabetes, researchers report.
<p>Nuclear medicine imaging significantly improves the ability to localize the tumor in ectopic Cushing's syndrome, according to a new systematic review.</p>
